On June 27, 2023 Mestag Therapeutics (‘Mestag’), an immunotherapy company focusing on fibroblast-immune interactions, and VIB, the leading life science research institute in Flanders, reported entering into an agreement under which Mestag obtains the exclusive worldwide rights to research, develop and commercialize a panel of single domain antibodies, also known as Nanobodies, to an undisclosed target that plays a central role in anti-cancer immunity (Press release, Mestag Therapeutics, JUN 27, 2023, View Source [SID1234632943]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, Mestag will be responsible for the research, development and commercialization of the antibodies, which are the outcome of many years of leading-edge research within VIB. In return, VIB will receive an upfront payment, future success-based milestones and royalty payments.

Susan Hill, PhD, Chief Executive Officer of Mestag Therapeutics, said, "We are delighted to partner with VIB, one of the premier research institutes in Europe and a leader in nanobody technology and cancer biology. This agreement further strengthens Mestag’s first-in-class pipeline and targets an exciting new area of fibroblast-immune cancer biology."

"We are thrilled to work with Mestag. Mestag brings together a unique expertise set in fibroblast-immune biology and a deep understanding of antibody engineering and development. The company is perfectly positioned to take this promising program forward," said Jérôme Van Biervliet, PhD, Managing Director of VIB.